Key Quantitative Figures

Financial Indebtedness Clarification:

  • Total amount outstanding under Loans/Revolving Facilities like Cash Credit from Banks/Financial Institutions: ₹800 crores as on September 30, 2026
  • Total financial indebtedness of the listed entity including short-term and long-term debt: ₹800 crores

Quarter Ended September 30, 2026 (Unaudited):

  • Revenue from Operations: ₹560.5 million
  • Other Income: ₹77.4 million
  • Total Income: ₹637.9 million
  • Total Expenses: ₹965.9 million
  • (Loss)/Profit before exceptional items and tax: (₹328.0) million
  • Exceptional items: (₹682.6) million
  • (Loss)/Profit Before Tax: (₹1,010.6) million
  • Total Tax Credit: (₹235.2) million
  • (Loss)/Profit for the Period: (₹775.4) million
  • Total Comprehensive (Loss)/Income for the Period: (₹783.2) million
  • Earnings Per Share (Basic & Diluted): (₹31.41)
  • Paid-up Equity Share Capital (Face Value ₹5 each): ₹123.4 million

Half Year Ended September 30, 2026 (Unaudited):

  • Revenue from Operations: ₹1,598.6 million
  • Other Income: ₹164.8 million
  • Total Income: ₹1,763.4 million
  • Total Expenses: ₹1,659.7 million
  • (Loss)/Profit before exceptional items and tax: ₹103.7 million
  • Exceptional items: (₹682.6) million
  • (Loss)/Profit Before Tax: (₹578.9) million
  • Total Tax Credit: (₹125.6) million
  • (Loss)/Profit for the Period: (₹453.3) million
  • Total Comprehensive (Loss)/Income for the Period: (₹461.1) million
  • Earnings Per Share (Basic & Diluted): (₹18.36)

Balance Sheet as at September 30, 2026 (Unaudited):

  • Total Assets: ₹22,776.6 million (vs. ₹9,782.7 million as at March 31, 2026)
  • Non-Current Assets: ₹17,527.3 million (including Intangible Assets: ₹13,042.6 million)
  • Current Assets: ₹5,249.3 million (including Inventories: ₹1,641.9 million; Cash and Cash Equivalents: ₹2,482.4 million)
  • Total Equity: ₹7,717.2 million (vs. ₹8,178.3 million as at March 31, 2026)
  • Non-Current Liabilities: ₹2,978.2 million (including Borrowings: ₹2,835.1 million)
  • Current Liabilities: ₹12,081.2 million (including Borrowings: ₹5,125.0 million; Trade Payables: ₹1,936.6 million)

Cash Flows for Half Year Ended September 30, 2026 (Unaudited):

  • Net Cash generated from operating activities: ₹1,381.9 million
  • Net cash used in investing activities: (₹7,368.9) million
  • Net cash generated from financing activities: ₹7,944.4 million
  • Net increase in Cash and Cash Equivalents: ₹1,957.4 million

Dates of Action

  • Digital Signature Date: November 04, 2026 (00:00:38 +05'30')
  • Quarter End: September 30, 2026
  • Half Year End: September 30, 2026
  • Audit Committee Meeting: November 3, 2026
  • Board Meeting for Rights Issue Approval: October 8, 2026 (subsequent to quarter end)
  • Asset Purchase Agreement with Pfizer: September 7, 2026
  • Exclusive Promotion and Distribution Agreement with NHPL: September 8, 2026

Parties Involved

  • BSE Limited (Regulatory Recipient)
  • Pfizer Inc., USA (Counterparty for Asset Purchase)
  • Pfizer Products Inc., USA (Counterparty for Asset Purchase)
  • Novartis Healthcare Private Limited (Counterparty for Distribution Agreement)
  • WaveRise Investments Limited (Acquirer 1 in SPA)
  • ChrysCapital Fund X (Acquirer 2 in SPA)
  • B S R & Co. LLP (Reviewing Chartered Accountants)

Purpose or Stated Rationale

The revised filing is being submitted solely to rectify an inadvertent omission in the heading of the table for 'Disclosure of Outstanding Default on Loans and Debt Securities' where the expression '(INR in crores)' was omitted. All other disclosures remain unchanged.

Financial and Operational Impact

Exceptional Items: ₹682.6 million for the quarter and half-year ended September 30, 2026, comprising ₹610.0 million arising from termination and related inventory purchase arrangements with a major customer, and ₹72.6 million relating to other transition and restructuring costs.

Business Developments Impact:

  • Acquisition of portfolio from Pfizer Inc., USA and Pfizer Products Inc., USA for ₹13,132.4 million (reflected in Intangible Assets)
  • Entry into Exclusive Promotion and Distribution Agreement with Novartis Healthcare Private Limited for upfront consideration
  • Termination of exclusive sales and distribution agreement with one major customer effective September 30, 2026

Capital Structure Impact:

  • Significant increase in borrowings: Non-current borrowings of ₹2,835.1 million and current borrowings of ₹5,125.0 million
  • Increase in intangible assets by ₹13,042.6 million due to Pfizer acquisition
  • Decrease in other equity from ₹8,054.9 million to ₹7,593.8 million due to quarterly loss

Forward-looking Information

Subsequent to the quarter ended September 30, 2026, the Board of Directors approved raising funds through a rights issue of partly paid-up equity shares of face value of ₹5 each. The company has business projections indicating sufficient future taxable income for recognition of deferred tax assets.

Related Party Transactions

For the half year ended September 30, 2026, related party transactions totaled ₹593.83 million, primarily with Novartis entities including royalty payments (₹9.42 million), NBS services (₹7.90 million), business support services (₹34.67 million), and purchase of stock in trade (₹526.57 million).

Governance Updates

  • Dr. Vikas Gupta appointed as Managing Director and Chief Executive Officer during the quarter
  • Mr. Bhagwat Singh Deora appointed as Chief Financial Officer during the quarter
  • Company adopted Employee Stock Option Scheme 2026 (ESOP 2026)
  • Company name changed from 'Novartis India Limited' to 'Evonile Pharma Limited' effective September 24, 2026